RBM1-72 | 1439377-31-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: RBM1-72
• 英文别名: (E,2R,3S)-2-aminooctadec-4-en-3-ol
• CAS: 1439377-31-7
• 化学式: C₁₈H₃₇NO
• 分子量: 283.498
• InChiKey: ZREXGWPJFRJAJU-XZIRQGAESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-十五炔 在 Schwartz's reagent 、 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 RBM1-72
  参考文献：
  名称：

  Straightforward Access to Spisulosine and 4,5-Dehydrospisulosine Stereoisomers: Probes for Profiling Ceramide Synthase Activities in Intact Cells

  摘要：

  A stereoselective synthesis of spisulosine (ES285) and 4,5-dehydrospisulosine stereoisomers is described. Hydrozirconation of 1-pentadecyne with Schwartz reagent, followed by diastereocontrolled addition to L- or D-alaninal afforded the required 2-amino-1,3-diol framework. The resulting sphingoid bases revealed as excellent probes for the profiling of ceramide synthase activity in intact cells. Among the sphingoid bases described in this work, spisulosine (ES285), RBM1-77, and RBM1-73 were the most suitable ones because of their highest acylation rates. These molecules should prove useful to study the role of the different ceramide synthases and the resulting N-acyl (dihydro)ceramides in cell fate.

  DOI：

  10.1021/jo400440z

文献信息

• Sphingoid compounds for prophylaxis and/or therapy of a viral infection
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US10688065B2

  公开（公告）日：2020-06-23

  Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

  本文提供了预防或治疗受试者病毒感染的方法。某些方面提供了向人等受试者施用鞘氨醇化合物（可选鞘氨醇）、激活生成鞘氨醇基（可选鞘氨醇）的活性成分；或抑制鞘氨醇基（可选鞘氨醇）降解的活性剂。通过增加施用组合物的受试者或受试者的局部（如鼻子或鼻子内部或其部分）的鞘氨醇浓度，可降低病毒感染受试者或其细胞的能力，从而达到预防病毒感染的目的。
• Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US11298412B2

  公开（公告）日：2022-04-12

  Provided are processes for the prevention or treatment of infection by SARS-CoV-2. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the airways, nose or interior of the nose or portion thereof, the ability or SARS-CoV-2 to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

  本文提供了预防或治疗 SARS-CoV-2 感染的方法。某些方面提供了对人等受试者施用鞘氨醇化合物（可选鞘氨醇）、激活鞘氨醇基（可选鞘氨醇）生成的活性成分；或抑制鞘氨醇基（可选鞘氨醇）降解的活性剂。通过增加受试者或受试者施用组合物的部位（如呼吸道、鼻腔或鼻腔内部或其部分）的鞘氨醇的局部浓度，可降低 SARS-CoV-2 感染受试者或其细胞的能力，从而起到预防病毒感染的作用。
• USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS
  申请人：YEDA RESEARCH AND DEVELOPMENT CO. LTD.

  公开号：US20150258043A1

  公开（公告）日：2015-09-17

  Methods of preventing or treating bacterial infections, including but not limited to Pseudomonas aeruginosa infections, by administering sphingoid long chain bases (LCB) are provided. The invention further relates to the use of sphingoid long chain bases, or pharmaceutical composition comprising same, for the treatment of lung diseases or disorders such as cystic fibrosis and chronic obstructive pulmonary disease.
• SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US20200113850A1

  公开（公告）日：2020-04-16

  Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
• SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US20220016222A1

  公开（公告）日：2022-01-20

  Provided are processes for the prevention or treatment of infection by SARS-CoV-2. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the airways, nose or interior of the nose or portion thereof, the ability or SARS-CoV-2 to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.